Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid

Headache. 2022 Apr;62(4):530-533. doi: 10.1111/head.14294. Epub 2022 Apr 6.
No abstract available

Keywords: chronic migraine; fremanezumab; onabotulinumtoxinA; topiramate; valproic acid.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal
  • Botulinum Toxins, Type A* / therapeutic use
  • Chronic Disease
  • Double-Blind Method
  • Humans
  • Migraine Disorders* / drug therapy
  • Topiramate
  • Treatment Outcome
  • Valproic Acid / adverse effects

Substances

  • Antibodies, Monoclonal
  • fremanezumab
  • Topiramate
  • Valproic Acid
  • Botulinum Toxins, Type A